These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20558271)

  • 1. Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.
    Chan M; Cheong TG; Kurunathan S; Chandrika M; Ledon T; Fando R; Lalitha P; Zainuddin ZF; Ravichandran M
    Microb Pathog; 2010 Nov; 49(5):211-6. PubMed ID: 20558271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation.
    Ravichandran M; Ali SA; Rashid NH; Kurunathan S; Yean CY; Ting LC; Bakar AS; Lalitha P; Zainuddin ZF
    Vaccine; 2006 May; 24(18):3750-61. PubMed ID: 16102875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of rtxA and rtxC mutants of auxotrophic O139 Vibrio cholerae.
    Cheong TG; Chan M; Kurunathan S; Ali SA; ZiNing T; Zainuddin ZF; Lalitha P; Ravichandran M
    Microb Pathog; 2010 Feb; 48(2):85-90. PubMed ID: 19900531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering.
    Cheng C; Zhou Y; Kan B; Wang Q; Rui Y
    Mol Med Rep; 2014 Jun; 9(6):2239-44. PubMed ID: 24676972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vibrio cholerae cytolysin is essential for high enterotoxicity and apoptosis induction produced by a cholera toxin gene-negative V. cholerae non-O1, non-O139 strain.
    Saka HA; Bidinost C; Sola C; Carranza P; Collino C; Ortiz S; Echenique JR; Bocco JL
    Microb Pathog; 2008 Feb; 44(2):118-28. PubMed ID: 17919878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodies.
    Attridge SR; Holmgren J
    Microb Pathog; 2009 Dec; 47(6):314-20. PubMed ID: 19818394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.
    Murugaiah C; Nik Mohd Noor NZ; Mustafa S; Manickam R; Pattabhiraman L
    PLoS One; 2014; 9(2):e81817. PubMed ID: 24505241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera.
    Ledón T; Ferrán B; Pérez C; Suzarte E; Vichi J; Marrero K; Oliva R; Fando R
    Microbes Infect; 2012 Sep; 14(11):968-78. PubMed ID: 22546527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.
    Häse CC; Thai LS; Boesman-Finkelstein M; Mar VL; Burnette WN; Kaslow HR; Stevens LA; Moss J; Finkelstein RA
    Infect Immun; 1994 Aug; 62(8):3051-7. PubMed ID: 8039872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.
    Xian TH; Sinniah K; Yean CY; Krishnamoorthy V; Bahari MB; Ravichandran M; Prabhakaran G
    BMC Immunol; 2020 May; 21(1):29. PubMed ID: 32450807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxin-coregulated pilus-loaded microparticles as a vaccine against Vibrio cholerae O139.
    Du Y; Jia WX; Liu L
    Chin Med J (Engl); 2004 Apr; 117(4):618-20. PubMed ID: 15109462
    [No Abstract]   [Full Text] [Related]  

  • 14. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
    Yan M; Liu G; Diao B; Qiu H; Zhang L; Liang W; Gao S; Kan B
    Vaccine; 2007 May; 25(20):4046-55. PubMed ID: 17428586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of non-O1/non-O139 Vibrio cholerae isolates and polymerase chain reaction analysis of their virulence factors.
    Lee YL; Hung PP; Tsai CA; Lin YH; Liu CE; Shi ZY
    J Microbiol Immunol Infect; 2007 Dec; 40(6):474-80. PubMed ID: 18087626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in the organization of the CTX genetic element in strains of Vibrio cholerae O139 Bengal isolated from Calcutta, India and Dhaka, Bangladesh and its possible link to the dissimilar incidence of O139 cholera in the two locales.
    Basu A; Mukhopadhyay AK; Sharma C; Jyot J; Gupta N; Ghosh A; Bhattacharya SK; Takeda Y; Faruque AS; Albert MJ; Balakrish Nair G
    Microb Pathog; 1998 Mar; 24(3):175-83. PubMed ID: 9514639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of histopathological features of Vibrio cholerae O1 El Tor and O139 Bengal infections in rabbit intestinal mucosa.
    Amin A; Ali A; Kurunathan S; Cheong TG; Al-Jashamy KA; Jaafar H; Zainuddin ZF; Ravichandran M; Lalitha P
    Histol Histopathol; 2009 May; 24(5):559-65. PubMed ID: 19283664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of an engineered bivalent vaccine strain consisting of Vibrio cholerae CT-B and LPS-O antigens.
    Yu X; Ma Q
    Chin J Biotechnol; 1994; 10(4):225-32. PubMed ID: 7780018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide.
    Attridge SR; Wallerström G; Li BL; Morona R; Holmgren J
    Vaccine; 2009 Feb; 27(7):1055-61. PubMed ID: 19100303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.